Results 141 to 150 of about 69,548 (299)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

CHROMATOGRAPHIC PROPERTIES OF GAMMA GLOBULIN: BEHAVIOR OF SERUM GAMMA MACROGLOBULINS* [PDF]

open access: bronze, 1960
Joseph LoSpalluto   +3 more
openalex   +1 more source

JAK–STAT inhibitory effect of IN‐115314, a novel small molecule inhibitor, and pharmacokinetic/pharmacodynamic study in canine

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose The JAK–STAT signalling pathway has been extensively spotlighted as a therapeutic target for various diseases. This study assessed the inhibitory effects of a novel small molecule, IN‐115314, on JAK–STAT pathway. Experimental Approach The IC50 values of IN‐115314 for JAK1–pSTAT3 and JAK2–pSTAT5 were determined in canine ...
Jae‐Hun Ahn   +16 more
wiley   +1 more source

Electrophoretic Analyses of Serum Proteins of the Albino Rat [PDF]

open access: yes, 1971
Author Institution: Department of Biology, Bowling Green State University, Bowling Green, Ohio 43403Study of the leukemias and polycythemia has been complicated by the inability to isolate pure preparations of suspected "control factors" of hemopoiesis ...
Graham, James D., McCormick, David F.
core  

Home - About - Disclaimer - Privacy